Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Science

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1349-7006.2010.01789.xPMID 21143701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recurrent Colorectal Cancer

  2011cited by this paper
• Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

  2008cited by this paper
• Current surgical treatment of squamous cell carcinoma of the head and neck.

  2007cited by this paper
• High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy

  2007cited by this paper
• Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma

  2006cited by this paper
• A Potent Immunogenic General Cancer Vaccine That Targets Survivin, an Inhibitor of Apoptosis Proteins

  2005cited by this paper
• Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.

  2005cited by this paper
• Survivin as prognostic factor in squamous cell carcinoma of the oral cavity.

  2005cited by this paper
• Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Survivin, versatile modulation of cell division and apoptosis in cancer

  2003cited by this paper
• Survivin expression in oral squamous cell carcinoma

  2003cited by this paper
• Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma1

  2002cited by this paper
• Improved generation of HLA class I/peptide tetramers.

  2002cited by this paper
• An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.

  2002cited by this paper
• Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

  2002cited by this paper
• Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy

  2001cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.

  2000cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Oral cancer in the UK: to screen or not to screen.

  1998cited by this paper
• Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.

  1998cited by this paper
• A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

  1997cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

  1994cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• Journal of Translational Medicine Comparative Study on the Immunogenicity between an Hla-a24-restricted Cytotoxic T-cell Epitope Derived from Survivin and That from Its Splice Variant Survivin-2b in Oral Cancer Patients

  year unknowncited by this paper

• Cholesterol-modified peptide nanomicelles as a promising platform for cancer therapy: A review.

  2025cites this paper
• Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study

  2025cites this paper
• Effect of human survivin‐2B‐specific cytotoxic CD8+ T lymphocytes on CD44+/− HSC‐2 and HSC‐3 oral cancer cells

  2025cites this paper
• Prognostic and clinicopathological significance of survivin in gynecological cancer

  2024cites this paper
• Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens

  2024cites this paper
• Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma

  2024cites this paper
• Alpha/beta-defensins influence on the humoral immunity and complications in cancer of the oral cavity and oropharynx.

  2024cites this paper
• Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.

  2023cites this paper
• Insight on common forms of cutaneous head and neck carcinoma (Review).

  2023cites this paper
• Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma—A Review

  2023cites this paper
• Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.

  2023cites this paper
• Pioneering 4,11-Dioxo-4,11-dihydro-1H-anthra[2,3-d]imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy.

  2023cites this paper
• Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives

  2023cites this paper
• Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications

  2023cites this paper
• Title: T-cell targeted immunotherapy against the tumor associated antigen survivin (BIRC5) as a potential neoadjuvant immunotherapy for triple negative breast cancer.

  2022cites this paper
• Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines

  2021cites this paper
• Vaccine-Based Immunotherapy for Head and Neck Cancers

  2021cites this paper
• DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor

  2021cites this paper
• Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin

  2021cites this paper
• Personalized cancer vaccination in head and neck cancer

  2020cites this paper
• Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer

  2020cites this paper
• Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review).

  2019cites this paper
• Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

  2019cites this paper
• Selective Neck Dissection and Survival in Pathologically Node-Positive Oral Squamous Cell Carcinoma

  2019cites this paper
• Exosomal survivin facilitates vesicle internalization

  2018cites this paper
• Survivin-Based Treatment Strategies for Squamous Cell Carcinoma

  2018influential citation
• Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo

  2018cites this paper
• Targeting Head and Neck Cancer by Vaccination

  2018influential citation
• Sensitization of Cancer Cells via Non-Viral Delivery of Apoptosis Inducing Proteins Using a Cationic Bolaamphiphile.

  2018cites this paper
• High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes

  2018cites this paper
• Survivin Gene as a Potential Marker in Premalignant and Malignant Lesions of Oral Cavity

  2018cites this paper
• Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses

  2018cites this paper
• Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission.

  2017cites this paper
• Induction and Analysis of Cytotoxic T-Lymphocytes that Recognize Autologous Oral Squamous Cell Carcinoma.

  2017cites this paper
• Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma

  2017cites this paper
• Survivin as a Therapeutic Target in Squamous Cell Carcinoma

  2017cites this paper
• Presage of oncolytic virotherapy for oral cancer with herpes simplex virus

  2016cites this paper
• Survivin: a unique target for tumor therapy

  2016cites this paper
• Survivin Modulators: An Updated Patent Review (2011-2015).

  2016cites this paper
• Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue

  2016cites this paper
• Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

  2016cites this paper
• Peptide vaccination therapy: Towards the next generation

  2016cites this paper
• SELF-AMPLIFYING RNA VECTORS ENCODING SURVIVIN AS ANTI-TUMORAL VACCINE CANDIDATES Relatore: Prof. Diego Maria Michele FORNASARI Correlatore: Prof. Antonio SICCARDI Coordinatore del Dottorato: Prof. Massimo LOCATI

  2016cites this paper
• Immunological Regulation of Human Cancer Stem Cells/Cancer-Initiating Cells

  2015cites this paper
• Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

  2015cites this paper
• IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia

  2015cites this paper
• Drug coated microneedles for minimally-invasive treatment of oral carcinomas: development and in vitro evaluation

  2015cites this paper
• Phase I Clinical Study of Survivin-Derived Peptide Vaccine for Patients with Advanced Gastrointestinal Cancers

  2015cites this paper
• Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.

  2015cites this paper
• Survivin as a Cancer Vaccine Target

  2014cites this paper
• Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.

  2014cites this paper
• Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer

  2014cites this paper
• Title: Targeting Survivin with YM155 (sepantronium bromide): A novel therapeutic strategy for paediatric acute myeloid leukemia

  2014cites this paper
• [The path to innovative drug development of cancer vaccine: from discovery of tumor antigens to clinical trials].

  2014cites this paper
• The role of the inhibitor of apoptosis protein Survivin in cellular radiation response

  2014cites this paper
• Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors

  2014cites this paper
• Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells

  2014cites this paper
• Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy.

  2013cites this paper
• Combined therapy with anti-CTLA-4 mAb and GWEPDDNPI peptide generates anti-survivin immunity.

  2013cites this paper
• An Indirubin Derivative, Indirubin-3′-Monoxime Suppresses Oral Cancer Tumorigenesis through the Downregulation of Survivin

  2013cites this paper
• Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA.

  2013cites this paper
• Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients.

  2013cites this paper
• Rationale Behind Survivin Inhibition as a Potential Therapeutic Strategy in Head and Neck Carcinoma too

  2013cites this paper
• Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

  2013cites this paper
• Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients

  2013cites this paper
• Fowlpox‐based survivin vaccination for malignant mesothelioma therapy

  2013cites this paper
• Phage-Displayed Recombinant Peptides for Non-Invasive Imaging Assessment of Tumor Responsiveness to Ionizing Radiation and Tyrosine Kinase Inhibitors

  2012cites this paper
• In vitro induction of specific CD8+ T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma.

  2012cites this paper
• Prime-Boost Vaccination with SA-4-1BBL Costimulatory Molecule and Survivin Eradicates Lung Carcinoma in CD8+ T and NK Cell Dependent Manner

  2012cites this paper
• Metastasis from oral cancer: an overview.

  2012cites this paper
• Survivin as a prognostic/predictive marker and molecular target in cancer therapy.

  2012cites this paper
• Trial watch

  2012cites this paper
• Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.

  2012cites this paper
• Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer

  2012cites this paper
• DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model

  2012cites this paper
• Peptides and peptide conjugates: therapeutics on the upward path.

  2012cites this paper
• Six degrees of separation: the oxygen effect in the development of radiosensitizers.

  2011cites this paper
• The treatment of oral cancer: an overview for dental professionals.

  2011cites this paper